Sector Gamma AS Raises Stake in CVS Health Corporation $CVS

Sector Gamma AS raised its stake in CVS Health Corporation (NYSE:CVS) by 13.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 177,599 shares of the pharmacy operator’s stock after buying an additional 21,397 shares during the quarter. CVS Health makes up approximately 3.2% of Sector Gamma AS’s investment portfolio, making the stock its 11th largest position. Sector Gamma AS’s holdings in CVS Health were worth $14,094,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in CVS. Sei Investments Co. grew its holdings in CVS Health by 17.4% in the 2nd quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock valued at $62,474,000 after buying an additional 134,535 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in CVS Health by 1.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock valued at $77,353,000 after buying an additional 13,329 shares in the last quarter. Treasurer of the State of North Carolina lifted its stake in shares of CVS Health by 1.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock valued at $40,358,000 after purchasing an additional 7,588 shares during the last quarter. HUB Investment Partners LLC increased its position in shares of CVS Health by 25.0% during the 2nd quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock worth $1,039,000 after purchasing an additional 3,011 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of CVS Health by 8.0% during the 2nd quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock worth $111,017,000 after purchasing an additional 119,439 shares during the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health said it is using Fluency’s enterprise AI platform to move autonomous agents from pilot projects into production, a sign it is working to cut administrative costs and improve workflow efficiency across the business. CVS is Using Fluency to Close Enterprise AI Deployment Gap
• Positive Sentiment: Aetna launched “Mental Health on Demand,” which gives members real-time access to care and ongoing support; the company highlighted very fast clinician connection times, underscoring stronger service delivery and potentially better member engagement. Aetna Launches Aetna Mental Health on Demand To Provide Real Time Access to Care and Ongoing Support
• Positive Sentiment: CVS Caremark expanded coverage options for GLP-1 weight-loss medications, a move that may support affordability for members while strengthening the company’s position in a fast-growing and closely watched drug category. CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications With Expanded Coverage Options

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of recent analyst reports. Morgan Stanley upped their target price on shares of CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a research report on Thursday, June 4th. JPMorgan Chase & Co. lifted their price target on shares of CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. The Goldman Sachs Group lifted their price target on shares of CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research report on Thursday, February 12th. Leerink Partners reiterated an “outperform” rating and set a $98.00 price target on shares of CVS Health in a research report on Thursday, March 5th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of CVS Health in a research report on Thursday. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $100.68.

CVS Health Price Performance

CVS opened at $100.38 on Friday. The stock’s 50-day moving average price is $86.32 and its 200 day moving average price is $80.63. CVS Health Corporation has a 12-month low of $58.50 and a 12-month high of $100.55. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The firm has a market cap of $128.08 billion, a price-to-earnings ratio of 44.22, a PEG ratio of 0.96 and a beta of 0.62.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same quarter in the prior year, the company earned $2.25 EPS. CVS Health’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 annualized dividend and a yield of 2.6%. CVS Health’s dividend payout ratio is presently 117.18%.

Insider Activity

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the sale, the director directly owned 6,213,261 shares in the company, valued at $586,842,501.45. This represents a 24.20% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by corporate insiders.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.